Patents-Review.com
ClassID:

20943 ⎘

A61K38/179 - page 2 - CPC Classification

Classification description:

Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Recent Application in this class:
#301
20210008284
2021-01-14

Pre-filled plastic syringe containing a VEGF antagonist

 #302
20210002364
2021-01-07

Transgene genetic tags and methods of use

 #303
20210000816
2021-01-07

USE OF CCR5 ANTAGONISTS ALONE OR IN COMBINATION THERAPY FOR THE TREATMENT OF CANCER

 #304
20200407415
2020-12-31

Activin receptor type IIB variants and methods of use thereof

 #305
20200405814
2020-12-31

Compositions and methods for treating pulmonary hypertension

 #306
20200397865
2020-12-24

Compositions and methods for treating pulmonary hypertension

 #307
20200390860
2020-12-17

Compositions and methods for treating pulmonary hypertension

 #308
20200384080
2020-12-10

Compositions and methods for treating pulmonary hypertension

 #309
20200375891
2020-12-03

BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE

 #310
20200368332
2020-11-26

METHOD OF ENHANCING VIRAL-MEDIATED GENE DELIVERY

 #311
20200368331
2020-11-26

Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals

 #312
20200361926
2020-11-19

COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

 #313
20200353041
2020-11-12

Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents

 #314
20200338361
2020-10-29

COMPOSITIONS AND METHODS FOR INDUCING NANOPARTICLE-MEDIATED MICROVASCULAR EMBOLIZATION FOR TUMORS

 #315
20200332012
2020-10-22

Antigen Binding Molecules That Bind EGFR, Vectors Encoding Same, and Uses Thereof

 #316
20200323955
2020-10-15

Methods for treating pulmonary hypertension with a ligand binding domain of a TGF-beta type II receptor

 #317
20200306340
2020-10-01

TGFBETA AND ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY

 #318
20200297799
2020-09-24

TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION USING SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES

 #319
20200289645
2020-09-17

TREATMENTS AND METHODS FOR CONTROLLING HYPERTENSION

 #320
20200262905
2020-08-20

DUAL PDGF/VEGF ANTAGONISTS

 #321
20200246438
2020-08-06

TARGETING GDF6 AND BMP SIGNALING FOR ANTI-MELANOMA THERAPY

 #322
20200246423
2020-08-06

Stable aqueous formulations of aflibercept

 #323
20200246388
2020-08-06

Method for enhancing expression of insulin like growth factor 1 receptor in mesenchymal stem cell, method for obtaining mesenchymal stem cell, and method for treating brain tissue damage

 #324
20200239862
2020-07-30

Pharmaceutical composition for prevention or treatment of heart failure

 #325
20200237862
2020-07-30

Liquid Formalation of a VEGF Antagonist

 #326
20200231942
2020-07-23

ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSID AND METHODS OF USE THEREOF

 #327
20200230218
2020-07-23

Methods of decreasing amyloid beta (Aβ) plaque deposition and hyperphosphorylated tau plaque deposition in Alzheimer's disease using a cystatin C fusion protein

 #328
20200208159
2020-07-02

Inhibition of SEMA3A in the prevention and treatment of ocular hyperpermeability

 #329
20200208124
2020-07-02

Methods for treating anemia in a subject in need thereof

 #330
20200199548
2020-06-25

Methods for treating anemia in a subject in need thereof

 #331
20200199547
2020-06-25

Methods for treating anemia in a subject in need thereof

 #332
20200199546
2020-06-25

ISOLATED GDF TRAP POLYPEPTIDE

 #333
20200199545
2020-06-25

SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGR3) POLYPEPTIDE FOR USE IN THE PREVENTION OR TREATMENT OF SKELETAL GROWTH RETARDATION DISORDERS

 #334
20200199186
2020-06-25

Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

 #335
20200190162
2020-06-18

Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof

 #336
20200188472
2020-06-18

CONJUGATES FOR IMMUNOTHERAPY

 #337
20200181218
2020-06-11

Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels

 #338
20200181217
2020-06-11

Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels

 #339
20200165583
2020-05-28

ISOLATED GDF TRAP POLYPEPTIDE

 #340
20200164029
2020-05-28

Endoglin peptides to treat fibrotic diseases

 #341
20200157194
2020-05-21

Human antibodies to GREM1

 #342
20200155638
2020-05-21

Enhancing Oxytocin Receptor Expression Using an Oxytocin Receptor Agonist and an Alk5 Antagonist

 #343
20200140520
2020-05-07

IMMUNOSUPPRESSIVE TGF-B SIGNAL CONVERTER

 #344
20200140504
2020-05-07

Peptide for toll-like receptor (TLR) inhibition and pharmaceutical composition comprising same

 #345
20200131246
2020-04-30

VEGF antagonist formulations suitable for intravitreal administration

 #346
20200129589
2020-04-30

Anti-angiogenic therapy of metastatic colorectal cancer

 #347
20200123566
2020-04-23

MULTIGENE CONSTRUCT FOR IMMUNE-MODULATORY PROTEIN EXPRESSION AND METHODS OF USE

 #348
20200121788
2020-04-23

Abituzumab for the treatment of colorectal cancer

 #349
20200115455
2020-04-16

Compositions and methods for targeted immunomodulatory antibodies and fusion proteins

 #350
20200115440
2020-04-16

Treatment of fibrodysplasia ossificans progressiva

 #351
20200113970
2020-04-16

Compositions and methods for promoting hair growth

 #352
20200109193
2020-04-09

Methods and compositions for treating ulcers

 #353
20200101157
2020-04-02

VITRO CELL CULTURE METHODS FOR BETA-THALASSEMIA USING ACTIVIN TYPE II RECEPTOR LIGAND TRAPS

 #354
20200101134
2020-04-02

METHODS FOR TREATING MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS AND ANEMIA

 #355
20200095553
2020-03-26

FORMULATION COMPRISING EXTRACELLULAR VESICLES, METHOD FOR PRODUCING THE SAME, AND USES THEREOF

 #356
20200071392
2020-03-05

Methods of treating cancer using bifunctional molecules that target growth factors

 #357
20200071383
2020-03-05

Methods for treating vascular eye disorders with ActRII antagonists

 #358
20200056186
2020-02-20

COMPOSITIONS COMPRISING SASP MODULATORS AND SENESCENCE ATTENUATORS AND USES THEREOF FOR MODULATING CELLULAR SENESCENCE

 #359
20200038512
2020-02-06

Tumor treatment methods using cells that localize to the tumor

 #360
20200031917
2020-01-30

Antibody and protein therapeutic formulations and uses thereof

 #361
20200022917
2020-01-23

COMPOSITIONS AND METHODS OF MANUFACTURING PROTEIN MICROPARTICLES

 #362
20200017572
2020-01-16

VEGF antagonist formulations suitable for intravitreal administration

 #363
20200016266
2020-01-16

Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment

 #364
20200016237
2020-01-16

Methods, compounds and compositions for modulating blood brain barrier integrity and re-myelination

 #365
20200001110
2020-01-02

COMPOSITIONS AND METHODS FOR INDUCING NANOPARTICLE-MEDIATED MICROVASCULAR EMBOLIZATION FOR TUMORS

 #366
20190388539
2019-12-26

Formulations of VEG antagonist fusion proteins and method of manufacturing them

 #367
20190388522
2019-12-26

METHODS FOR TREATING DISORDERS ASSOCIATED WITH ANGIOGENESIS AND NEOVASCULARIZATION

 #368
20190375810
2019-12-12

Erythropoietin-derived peptides and methods of protecting cells from oxidative damage induced by reactive oxygen species

 #369
20190367929
2019-12-05

CTLA4/PD1 targeted/immunomodulatory fusion proteins

 #370
20190352619
2019-11-21

ACTRIIB-FC POLYNUCLEOTIDES, POLYPEPTIDES, AND COMPOSITIONS

 #371
20190343925
2019-11-14

Synergistic tumor treatment with an extended pharmacokinetic IL-2 and integrin-binding-Fc fusion protein

 #372
20190343918
2019-11-14

High concentration VEGF receptor fusion protein containing formulations

 #373
20190298801
2019-10-03

Aflibercept formulations and uses thereof

 #374
20190298780
2019-10-03

Methods and compositions for treating inflammatory skin disease with recombinant microorganisms

 #375
20190290725
2019-09-26

Use of a VEGF antagonist to treat angiogenic eye disorders

 #376
20190285653
2019-09-19

Treatment for age-related macular degeneration (AMD) and pathogenic ocular neovascularization

 #377
20190276528
2019-09-12

Stable aqueous formulations of aflibercept

 #378
20190275160
2019-09-12

BONE-TARGETING THERAPEUTIC CONJUGATE AND METHODS OF MAKING AND USING THE SAME

 #379
20190275106
2019-09-12

Anti-Angiogenic Gene Therapy Kit

 #380
20190263876
2019-08-29

Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels

 #381
20190262423
2019-08-29

ACTIVIN-ACTRII ANTAGONISTS AND USES FOR TREATING BONE AND OTHER DISORDERS

 #382
20190249163
2019-08-15

Delivery of therapeutic agents by a collagen binding protein

 #383
20190248891
2019-08-15

Drug regulated transgene expression

 #384
20190247463
2019-08-15

Use of a VEGF antagonist to treat angiogenic eye disorders

 #385
20190233486
2019-08-01

Methods for treating myelodysplastic syndromes and sideroblastic anemias

 #386
20190218273
2019-07-18

Nucleic acid encoding angiopoietin-2 specific Tie2 receptor

 #387
20190203188
2019-07-04

Fusion proteins and methods thereof

 #388
20190202894
2019-07-04

Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR

 #389
20190201450
2019-07-04

Method for treating multiple sclerosis

 #390
20190192625
2019-06-27

Method for promoting bone growth using activin-actriia antagonists

 #391
20190169621
2019-06-06

Immunotherapy methods using anti-PD-L1 antibodies in combination with EGFR1 targeted-TGF-beta immunomodulatory fusion proteins

 #392
20190161532
2019-05-30

HCMV entry inhibitors

 #393
20190160145
2019-05-30

Aflibercept ophthalmic pharmaceutical composition

 #394
20190160144
2019-05-30

ActRIIB:Fc to treat infertility in females

 #395
20190151409
2019-05-23

TREATMENT OF AMD USING AAV2 VARIANT WITH AFLIBERCEPT

 #396
20190151404
2019-05-23

THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEEASE

 #397
20190142868
2019-05-16

METHODS OF TREATING DISEASES ASSOCIATED WITH ILC3 CELLS

 #398
20190119382
2019-04-25

Polynucleotides encoding bispecific chimeric antigen receptors

 #399
20190117767
2019-04-25

Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab

 #400
20190106497
2019-04-11

Antigen Binding Molecules That Bind EGFR, Vectors Encoding Same, and Uses Thereof

 #401
20190077855
2019-03-14

Compositions and methods for targeting activin signaling to treat cancer

 #402
20190070213
2019-03-07

Antisense oligomers and uses thereof

 #403
20190060429
2019-02-28

Vaccine for the prevention of breast cancer relapse

 #404
20190055318
2019-02-21

Eliminating MHC restriction from the T cell receptor as a strategy for immunotherapy

 #405
20190046609
2019-02-14

Use of a VEGF antagonist to treat angiogenic eye disorders

 #406
20190046603
2019-02-14

Therapeutic compositions for the treatment of dry eye disease

 #407
20190038746
2019-02-07

Stable liquid formulations of recombinant fusion proteins

 #408
20190031735
2019-01-31

VEGF antagonist formulations suitable for intravitreal administration

 #409
20190030123
2019-01-31

Liquid formulation of a VEGF antagonist

 #410
20190000920
2019-01-03

Methods of treating lung cancer

 #411
20190000919
2019-01-03

Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist

 #412
20180371418
2018-12-27

Formulation comprising extracellular vesicles, method for producing the same, and uses thereof

 #413
20180369329
2018-12-27

Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator

 #414
20180339018
2018-11-29

Use of a VEGF antagonist to treat angiogenic eye disorders

 #415
20180318431
2018-11-08

Methods of treating an ocular disease or disorder

 #416
20180318386
2018-11-08

PEPTIDES AND METHODS OF TREATING ENDOMETRIOSIS USING THE SAME

 #417
20180312559
2018-11-01

METHODS FOR TREATING REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS

 #418
20180311319
2018-11-01

TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS

 #419
20180298078
2018-10-18

Method for producing fusion protein having IgG Fc domain

 #420
20180296651
2018-10-18

Method of treating macular degeneration using botulinum toxin-based pharmaceuticals

 #421
20180289825
2018-10-11

Single chain Fc fusion proteins

 #422
20180289689
2018-10-11

USE OF CCR5 ANTAGONISTS ALONE OR IN COMBINATION THERAPY FOR THE TREATMENT OF CANCER

 #423
20180280470
2018-10-04

METHODS OF TREATING CANCER

 #424
20180258156
2018-09-13

Endoglin polypeptides and uses thereof

 #425
20180251457
2018-09-06

COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

 #426
20180250361
2018-09-06

Methods, compounds and compositions for modulating blood brain barrier integrity and re-myelination

 #427
20180244783
2018-08-30

COMBINATION THERAPY FOR TREATMENT OF DISEASE

 #428
20180244762
2018-08-30

Dual PDGF/VEGF antagonists

 #429
20180237497
2018-08-23

Insulin-like growth factor 2 (IGF2) binding agents

 #430
20180237431
2018-08-23

COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

 #431
20180237430
2018-08-23

COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

 #432
20180237429
2018-08-23

COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

 #433
20180236070
2018-08-23

Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody

 #434
20180230197
2018-08-16

Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof

 #435
20180221447
2018-08-09

Compositions and methods for treating pulmonary hypertension

 #436
20180208647
2018-07-26

VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMORS

 #437
20180200352
2018-07-19

Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity

 #438
20180200350
2018-07-19

Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity

 #439
20180194834
2018-07-12

Methods for treating ulcers in a hemoglobinopathy anemia with a soluble actRIIB polypeptide

 #440
20180194828
2018-07-12

ACTRIIB ANTAGONISTS AND DOSING AND USES THEREOF

 #441
20180170996
2018-06-21

Method of treatment of cerebral amyloid angiopathy with P75ECD peptide and/or P75ECD-FC fusion protein

 #442
20180169188
2018-06-21

Treatment of X-linked hypohidrotic ectodermal dysplasia with a fusion EDA1 protein

 #443
20180162928
2018-06-14

PD-L1 binding fibronectin type III domains

 #444
20180161426
2018-06-14

In vitro cell culture methods for beta-thalassemia using activin type II receptor ligand traps

 #445
20180161407
2018-06-14

Method of treating macular degeneration using botulinum toxin-based pharmaceuticals

 #446
20180161392
2018-06-14

Therapeutic use of p75NTR neurotrophin binding protein

 #447
20180155439
2018-06-07

Compositions and Conjugates Comprising an Interleukin and Polypeptides That Specifically Bind TGF-beta

 #448
20180155408
2018-06-07

VEGF antagonist formulations suitable for intravitreal administration

 #449
20180148494
2018-05-31

SOLUBLE FGFR3 DECOYS FOR TREATING SKELETAL GROWTH DISORDERS

 #450
20180147258
2018-05-31

Stable liquid formulations of recombinant fusion proteins

 #451
20180133312
2018-05-17

Combination of anti-FGFR4-antibody and bile acid sequestrant

 #452
20180133288
2018-05-17

Method for treating eye diseases with a fusion protein of a tissue-penetrating peptide and anti-vascular endothelial growth factor

 #453
20180133259
2018-05-17

Method for enhancing insulin like growth factor 1 receptor expression of mesenchymal stem cell, method for isolating mesenchymal stem cell, and use of mesenchymal stem cell

 #454
20180125948
2018-05-10

Treatment of ocular neovascularization using anti-VEGF proteins

 #455
20180125928
2018-05-10

TREATMENT OF BETA-THALASSEMIA USING ACTRII LIGAND TRAPS

 #456
20180116975
2018-05-03

COMPOSITIONS AND COMBINATIONS FOR THE TREATMENT OF ANGIOGENESIS DISEASES AND DISORDERS

 #457
20180113134
2018-04-26

METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER BY MEASURING THE LEVEL OF A PLASMA BIOMARKER

 #458
20180112192
2018-04-26

PINK1 C-terminal domain polypeptide and methods using the same in cancer treatment

 #459
20180111983
2018-04-26

Treatment of Fibrodysplasia Ossificans Progressiva

 #460
20180104307
2018-04-19

Targeting GIV-GEF-GI signaling for treating diverse diseases

 #461
20180094051
2018-04-05

METHOD FOR INHIBITING LYMPHANGIOGENESIS BY ADMINISTRATION OF AN INHIBITOR OF THE CXCL12 PATHWAY

 #462
20180078496
2018-03-22

ARTICLE OF MANUFACTURE COMPRISING AFLIBERCEPT OR ZIV-AFLIBERCEPT

 #463
20180066057
2018-03-08

Epidermal growth factor receptor targeted/immunomodulatory fusion proteins and methods of use for them

 #464
20180064828
2018-03-08

Methods for the diagnosis and treatment of Sjögren's syndrome

 #465
20180050089
2018-02-22

Compositions and methods for treating pulmonary hypertension

 #466
20180050085
2018-02-22

METHODS AND COMPOSITIONS FOR TREATING MYELOFIBROSIS

 #467
20180044389
2018-02-15

Compositions for regulating iron homeostasis and methods of using same

 #468
20180037622
2018-02-08

Methods for treating refractory anemia with ringed sideroblasts

 #469
20180030455
2018-02-01

Inhibition of SEMA3A in the prevention and treatment of ocular hyperpermeability

 #470
20180028651
2018-02-01

Combination therapy for treatment of coronary artery disease

 #471
20180028609
2018-02-01

Antibody which binds Lrg1 and methods of use

 #472
20180022741
2018-01-25

COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

 #473
20180021406
2018-01-25

Methods for treating back or neck pain caused by NGF using a therapeutic agent comprising REN-1820, ALE-0540 and capsaicin

 #474
20180009891
2018-01-11

Method and compositions for cellular immunotherapy

 #475
20180008716
2018-01-11

Somatostatin receptor-based cancer therapy

 #476
20180002399
2018-01-04

FGFR1 EXTRACELLULAR DOMAIN COMBINATION THERAPIES

 #477
20170368103
2017-12-28

Composition including stem cell-derived microvesicles for promoting neurogenesis

 #478
20170361126
2017-12-21

Compositions and Methods for Inducing Nanoparticle Mediated Microvascular Embolization of Tumors

 #479
20170360930
2017-12-21

Method of manufacturing VEGF antagonist fusion proteins

 #480
20170360887
2017-12-21

Activin-ActRII antagonists and uses for treating anemia

 #481
20170342123
2017-11-30

Immunotherapy against ErbB-3 receptor

 #482
20170327574
2017-11-16

Methods of treating liver conditions using Notch2 antagonists

 #483
20170319669
2017-11-09

METHOD OF ENHANCING VIRAL-MEDIATED GENE DELIVERY

 #484
20170306006
2017-10-26

Human Notch1 decoys

 #485
20170304397
2017-10-26

Treatment of cardiovascular disease using ActRII ligand traps

 #486
20170281725
2017-10-05

Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

 #487
20170275340
2017-09-28

Anti-cancer compositions containing Wnt decoy receptor

 #488
20170274077
2017-09-28

Methods for increasing red blood cell levels and treating ineffective erythropoiesis

 #489
20170274001
2017-09-28

Compositions and Methods for Increasing Red Blood Cells

 #490
20170267742
2017-09-21

Transgene genetic tags and methods of use

 #491
20170266318
2017-09-21

Hydrogel microspheres containing peptide ligands for growth factor regulation in blood products

 #492
20170240614
2017-08-24

Blood glucose lowering compound

 #493
20170233747
2017-08-17

Targeted/TGF-ßRII fusion proteins and methods for making same

 #494
20170232199
2017-08-17

Pre-Filled Plastic Syringe Containing a VEGF Antagonist

 #495
20170224740
2017-08-10

Methods for treating traumatic brain injury with amnion-derived cellular cytokine solution (ACCS) or amnion-derived multipotent progenitor (AMP) cells

 #496
20170216402
2017-08-03

Synergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein

 #497
20170210813
2017-07-27

Anti-PDGFR-beta antibodies and uses thereof

 #498
20170204390
2017-07-20

Delivery of therapeutic agents by a collagen binding protein

 #499
20170204382
2017-07-20

Methods of identifying ActRIIB variants

 #500
20170202913
2017-07-20

CTL INDUCER COMPOSITION

 #501
20170202911
2017-07-20

Use of a VEGF antagonist to treat angiogenic eye disorders

 #502
20170202909
2017-07-20

Formulated Receptor Polypeptides and Related Methods

 #503
20170202902
2017-07-20

Conjugates for immunotherapy

 #504
20170189479
2017-07-06

Syndecan-4 proteoliposomes for enhanced cutaneous wound healing and minimized inflammatory immune response

 #505
20170181978
2017-06-29

Polymer protein microparticles

 #506
20170165285
2017-06-15

METHODS OF PREVENTING TUMOR METASTASIS, TREATING AND PROGNOSING CANCER AND IDENTIFYING AGENTS WHICH ARE PUTATIVE METASTASIS INHIBITORS

 #507
20170158770
2017-06-08

Compositions and methods for targeted immunomodulatory antibodies and fusion proteins

 #508
20170152299
2017-06-01

Human FGFR2B extracellular domain and nucleic acid for coding same

 #509
20170152297
2017-06-01

Drug regulated transgene expression

 #510
20170145085
2017-05-25

Method of promoting bone growth by an anti-actriia antibody

 #511
20170145074
2017-05-25

ACTIVIN-ACTRIIA ANTAGONISTS AND USES FOR TREATING OR PREVENTING BREAST CANCER

 #512
20170107285
2017-04-20

Bispecific chimeric antigen receptors and methods of use thereof to treat cancer

 #513
20170081387
2017-03-23

Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof

 #514
20170080086
2017-03-23

METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES

 #515
20170072031
2017-03-16

Nanoparticles comprising aminoacyl tRNA synthetase and anticancer composition comprising same

 #516
20170066838
2017-03-09

Chimeric antigen receptor

 #517
20170056469
2017-03-02

INDIVIDUALIZED TREATMENT OF EYE DISEASE

 #518
20170044504
2017-02-16

Adeno-associated virus virions with variant capsid and methods of use thereof

 #519
20170020958
2017-01-26

STEM CELLS FOR ANTI-ANGIOGENIC THERAPY IN AGE-RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, CORNEAL VASCULARISATION AND CANCER

 #520
20170020924
2017-01-26

MESENCHYMAL STEM CELL, METHOD FOR CLONOGENIC EXPANSION THEREOF, METHOD FOR ISOLATING THEREOF, AND USE THEREOF

 #521
20160376342
2016-12-29

Stable liquid formulation of fusion protein with IgG Fc domain

 #522
20160333418
2016-11-17

Activin Inhibitor Response Prediction and Uses for Treatment

 #523
20160331807
2016-11-17

THERAPEUTIC USE OF VEGFR-3 LIGANDS

 #524
20160326228
2016-11-10

Isolated nucleotide sequences encoding GDF traps

 #525
20160324898
2016-11-10

COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

 #526
20160304968
2016-10-20

Identification of Predictive Biomarkers Associated With WNT Pathway Inhibitors

 #527
20160304614
2016-10-20

Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof

 #528
20160297867
2016-10-13

ALK7:ActRIIB heteromultimers and uses thereof

 #529
20160289286
2016-10-06

Methods for treating myelodysplastic syndromes and sideroblastic anemias

 #530
20160287664
2016-10-06

Methods for treating pulmonary hypertension with a TGF-beta type II receptor-FC fusion protein

 #531
20160264969
2016-09-15

METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES

 #532
20160256519
2016-09-08

Therapeutic compositions for the treatment of dry eye disease

 #533
20160250287
2016-09-01

Methods of treating and preventing cancer drug resistance

 #534
20160244505
2016-08-25

VEGF antagonist formulations suitable for intravitreal administration

 #535
20160244504
2016-08-25

VEGF specific fusion protein antagonist formulations

 #536
20160243225
2016-08-25

Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibody

 #537
20160237155
2016-08-18

Anti-CTLA4 antibody-TGF-βRII targeted/immunomodulatory fusion proteins

 #538
20160228495
2016-08-11

Targeting the EGFR-SGLT1 interaction for cancer therapy

 #539
20160220540
2016-08-04

COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

 #540
20160213608
2016-07-28

VEGF antagonist formulations suitable for intravitreal administration

 #541
20160194370
2016-07-07

Method of improving the pharmacokinetic profile of a therapeutic polypeptide and the use thereof

 #542
20160184393
2016-06-30

Treatment of X-linked hypohidrotic ectodermal dysplasia with a fusion EDA1 protein

 #543
20160175458
2016-06-23

SINGLE CHAIN FC FUSION PROTEINS

 #544
20160175439
2016-06-23

Stable VEGF antagonist formulations

 #545
20160168260
2016-06-16

Method of treating cancer with an EGFR targeted immunomodulatory fusion protein

 #546
20160158316
2016-06-09

DRG11-RESPONSIVE (DRAGON) GENE FAMILY

 #547
20160137717
2016-05-19

USE OF A VEGF ANTAGONIST IN TREATING CHOROIDAL NEOVASCULARISATION

 #548
20160130321
2016-05-12

USE OF A VEGF ANTAGONIST IN TREATING MACULAR EDEMA

 #549
20160129080
2016-05-12

TREATMENT OF POLYPOIDAL CHROIDAL VASCULOPATHY

 #550
20160122433
2016-05-05

Anti-PDGFR-beta antibodies and uses thereof

 #551
20160120939
2016-05-05

Method of identifying an agent that promotes bone growth or increases bone density

 #552
20160108380
2016-04-21

Fusion proteins and methods thereof

 #553
20160106809
2016-04-21

Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD

 #554
20160101152
2016-04-14

Use of a VEGF antagonist to treat angiogenic eye disorders

 #555
20160101151
2016-04-14

Compounds and methods of modulating angiogenesis

 #556
20160084853
2016-03-24

Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis

 #557
20160075755
2016-03-17

Immunosuppressive TGF-β signal converter

 #558
20160067307
2016-03-10

METHODS OF TREATING CANCER

 #559
20160060346
2016-03-03

Modulation of Activity of Proneurotrophins

 #560
20160058828
2016-03-03

Methods, uses and compositions of Tie2 agonists

 #561
20160024195
2016-01-28

Human antibodies to GREM1

 #562
20160002641
2016-01-07

Inhibition of SEMA3A in the prevention and treatment of ocular hyperpermeability

 #563
20160000873
2016-01-07

AGENTS WHICH INDUCE LYMPHANGIOGENESIS FOR USE IN THE TREATMENT OF CYSTIC KIDNEY DISEASE

 #564
20160000865
2016-01-07

Compositions and methods relating to induction of intestinal stem cell homeogenesis and/or regeneration

 #565
20150376271
2015-12-31

Dual PDGF/VEGF antagonists

 #566
20150359850
2015-12-17

ADMINISTRATION OF AN ANTI-ACTIVIN-A COMPOUND TO A SUBJECT

 #567
20150353624
2015-12-10

Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders

 #568
20150328312
2015-11-19

Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof

 #569
20150322414
2015-11-12

Angiopoietin-2 specific TIE2 receptor

 #570
20150297675
2015-10-22

USE OF A VEGF ANTAGONIST IN TREATING OCULAR VASCULAR PROLIFERATIVE DISEASES

 #571
20150297402
2015-10-22

Implantable therapeutic device

 #572
20150283209
2015-10-08

Activin-ActRII antagonists and uses for treating bone and other disorders

 #573
20150283206
2015-10-08

Treatment selection for lung cancer patients using mass spectrum of blood-based sample

 #574
20150273083
2015-10-01

Methods for the diagnosis and treatment of sjögren's syndrome

 #575
20150247135
2015-09-03

Broad spectrum ErBB ligand binding molecules and methods for preparing and using them

 #576
20150246964
2015-09-03

Antibodies that specifically bind to DRG11-responsive (DRAGON) proteins

 #577
20150238568
2015-08-27

EXENDINS TO LOWER CHOLESTEROL AND TRIGLYCERIDES

 #578
20150231206
2015-08-20

VARIANT ACTIVIN RECEPTOR POLYPEPTIDES AND USES THEREOF

 #579
20150216795
2015-08-06

ARTICLE OF MANUFACTURE COMPRISING AFLIBERCEPT OR ZIV-AFLIBERCEPT

 #580
20150203566
2015-07-23

FGFR1 EXTRACELLULAR DOMAIN COMBINATION THERAPIES

 #581
20150202260
2015-07-23

ENDOGLIN PEPTIDES TO TREAT FIBROTIC DISEASES

 #582
20150182609
2015-07-02

Vaccine for the prevention of breast cancer relapse

 #583
20150111821
2015-04-23

Mutated fibroblast growth factor (FGF) 1 and methods of use

 #584
20150079087
2015-03-19

Stable liquid formulations of dimer VEGF antagonists

 #585
20150073381
2015-03-12

Encapsulated cell therapy cartridge

 #586
20150051378
2015-02-19

Antibodies that specifically bind to DRG11-responsive (dragon) proteins

 #587
20150050277
2015-02-19

COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES

 #588
20150045298
2015-02-12

COMPOSITION INCLUDING STEM CELL-DERIVED MICROVESICLES FOR PROMOTING NEUROGENESIS

 #589
20150038684
2015-02-05

Bispecific chimeric antigen receptors and encoding polynucleotides thereof

 #590
20150037335
2015-02-05

Therapeutic use of p75NTR neurotrophin binding protein

 #591
20150004101
2015-01-01

Treatment of ocular neovascularization using anti-VEGF proteins

 #592
20140377215
2014-12-25

Delivery of therapeutic agents by a collagen binding protein

 #593
20140363432
2014-12-11

VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF

 #594
20140348827
2014-11-27

Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof

 #595
20140341900
2014-11-20

Methods of treating lung cancer

 #596
20140341846
2014-11-20

METHODS OF INHIBITING PHOTORECEPTOR APOPTOSIS

 #597
20140336129
2014-11-13

Targeting the EGFR-SGLT1 interaction for cancer therapy

 #598
20140335155
2014-11-13

Composition for improving skin conditions, containing extracellular domain of human bone morphogenetic protein receptor 1a as active ingredient

 #599
20140328860
2014-11-06

Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling

 #600
20140315825
2014-10-23

Anti-cancer compositions containing WNT decoy receptor